Delving into the Latest Updates on ZMPB-NK006 with Synapse

Overview

Basic Info

Drug Type

Natural Killer Cell Therapies

Synonyms

NK-006, ZMPB-NK006

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Hebei Meiou Saiaojin Biotechnology Co., Ltd.

Active Organization

Hebei Meiou Saiaojin Biotechnology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评估ZMPB-NK006注射液在晚期或转移性恶性实体肿瘤患者中的安全性和耐受性。次要目的：评估ZMPB-NK006注射液在晚期或转移性恶性实体肿瘤患者中的药代动力学（PK）特征；评估ZMPB-NK006注射液在晚期或转移性恶性实体肿瘤患者中的免疫原性；评估ZMPB-NK006注射液在晚期或转移性恶性实体肿瘤患者中的初步抗肿瘤活性。探索性目的：探索ZMPB-NK006注射液在晚期或转移性恶性肿瘤患者中的药效学，以及与ZMPB-NK006注射液的疗效和安全性之间的相关性。

[Translation]

Primary objective: To evaluate the safety and tolerability of ZMPB-NK006 injection in patients with advanced or metastatic malignant solid tumors. Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics of ZMPB-NK006 injection in patients with advanced or metastatic malignant solid tumors; to evaluate the immunogenicity of ZMPB-NK006 injection in patients with advanced or metastatic malignant solid tumors; and to evaluate the preliminary antitumor activity of ZMPB-NK006 injection in patients with advanced or metastatic malignant solid tumors. Exploratory objective: To explore the pharmacodynamics of ZMPB-NK006 injection in patients with advanced or metastatic malignant tumors, and its correlation with the efficacy and safety of ZMPB-NK006 injection.

Start Date-

Sponsor / Collaborator

Hebei Meiou Saiaojin Biotechnology Co., Ltd.

100 Clinical Results associated with ZMPB-NK006

Login to view more data

100 Translational Medicine associated with ZMPB-NK006

Login to view more data

100 Patents (Medical) associated with ZMPB-NK006

Login to view more data

100 Deals associated with ZMPB-NK006

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Malignant Solid Neoplasm	Phase 1	China	Hebei Meiou Saiaojin Biotechnology Co., Ltd.	14 Jan 2026
Advanced Malignant Solid Neoplasm	IND Approval	China	Hebei Meiou Saiaojin Biotechnology Co., Ltd.	31 Mar 2025